Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients

BACKGROUND: Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients’ outcomes. Nevertheless, many patients are resistant to PD-1 inhibition, occasionally experiencing severe off-target immune toxicity. In addition, no robust and reproducible biomarkers have yet...

Descripción completa

Detalles Bibliográficos
Autores principales: Galati, Domenico, Zanotta, Serena, Capone, Mariaelena, Madonna, Gabriele, Mallardo, Domenico, Romanelli, Marilena, Simeone, Ester, Festino, Lucia, Sparano, Francesca, Azzaro, Rosa, De Filippi, Rosaria, Pinto, Antonio, Paulos, Chrystal M., Ascierto, Paolo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176780/
https://www.ncbi.nlm.nih.gov/pubmed/37170241
http://dx.doi.org/10.1186/s12967-023-04184-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176780/
https://www.ncbi.nlm.nih.gov/pubmed/37170241
http://dx.doi.org/10.1186/s12967-023-04184-6

Ejemplares similares